Antiphospholipid antibody: Laboratory, pathogenesis and clinical manifestations;Gli anticorpi antifosfolipidi: Il laboratorio, la patogenesi e la clinica (cosa è utile sapere degli anticorpi antifosfolipidi)

Reumatismo

Volumn 62, Issue 1, 2010, Pages 65-75

  Tincani, A ^a   Casu, C ^a   Cartella, S ^a   Ziglioli, T ^a   Cattaneo, R ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Anti 2gpi; Anticardiolipin; Antiphospholipid antibodies; Lupus anticoagulant; Pathogenetic hypothesis

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; COMPLEMENT; LIPOCORTIN 2; LIPOCORTIN 5; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTHROMBIN ANTIBODY; TOLL LIKE RECEPTOR;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; CELL ADHESION; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS WASTAGE; FIBRINOLYSIS; HUMAN; IMMUNOPATHOGENESIS; LABORATORY DIAGNOSIS; PHENOTYPE; PREGNANCY COMPLICATION; TROPHOBLAST; VEIN THROMBOSIS;

ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; BLOOD COAGULATION TESTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FETAL DEATH; HUMANS; LUPUS COAGULATION INHIBITOR; PATIENT SELECTION; PREGNANCY; PREGNANCY COMPLICATIONS; RISK ASSESSMENT; RISK FACTORS; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOSIS;

EID: 77953694592     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Galli M, Comfurius P, Maassen C, Hemker HC, de Ba-ets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-47.
2. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-32.
3. Oosting JD, Derksen RH, Bobbink IW, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood. 1993; 81: 2618-25.
4. Chen XX, Gu YY, Li SJ, Qian J, Hwang KK, Chen PP et al. Some plasmin-induced antibodies bind to cardi-olipin, display lupus anticoagulant activity and induce fetal loss in mice. J Immunol. 2007; 178: 5351-56.
5. Cesarman-Maus G, Rios-Luna NP, Deora AB, Huang B, Villa R, Cravioto Mdel C et al. Autoantibodies against the fibrinolytic receptor, anexin A2, in an-tiphospholipid syndrome. Blood. 2006; 107: 4375-82.
6. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagu-lant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-90.
7. Pengo V, Tripodi A, Reber G, Rand J. H, Ortel T L, Galli M, et al. Update of the guidelines for Lupus An-ticoagulant detection. Journal of Thromb Haemost 2009; 7: 1737-40.
8. Tincani A, Balestrieri G, Spatola L, Cinquini M, Me-roni PL, Roubev RA. Anticardiolipin and anti-beta 2glycoprotein I immunoassays in the diagnosis of an-tiphospholipid syndrome. Clin Exp Rheumatol 1998; 396-402.
9. Tincani A, Allegri F, Sanmarco M, Cinquini M, Ta-glietti M, Balestrieri G, et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001; 86: 575-83.
10. Harris EN, Pierangeli SS. Revisiting the anticardiolipin test and its standardization. Lupus 2002; 11: 269-75.
11. Wong RC, Gillis D, Adelstein S, Baumgart K, Faval-oro EJ, Hendle MJ, et al. Consensus guidelines on an-ticardiolipin antibody testing and reporting. Pathology 2004; 36: 63-8.
12. Tincani A, Allegri F, Balestrieri G, Reber G, Sanmar-co M, Meroni P, et al. Minimal requirements for an-tiphospholipid antibodies ELISAs proposed by the Eu-ropean Forum on antiphospholipid antibodies. Thromb Res 2004; 114: 553-8.
13. Andreoli L, Rizzini S, Allegri F, Meroni P, Tincani A. Are the current attempts at standardization of an-tiphospholipid antibodies still useful? Emerging tech-nologies signal a shift in direction. Semin Thromb He-most 2008; 34: 356-60.
14. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid sindrome. Blood 2003; 102: 2717-23.
15. Reber G, de Moerloose P. Anti-beta 2-glycoprotein I antibodies-when and how should they be measured? Thromb Res 2004; 114: 527-31.
16. Faden D, Tincani A, Tanzi P, Spatola L, Lojacono A, Tarantini M, et al. Anti-beta 2-glycoprotein I antibod-ies in a general obstetric population: preliminary re-sults on the prevalence and correlation with pregnancy outcome. Anti-beta 2-glycoprotein I antibodies are as-sociated with some obstetrical complications, mainly preeclampsia-eclampsia. Eur J Obstet Gynecol Reprod Biol 1997; 73: 37-42.
17. Lee RM, Branch DW, Silver RM. Immunoglobulin A anti-beta 2-glycoprotein I antibodies in women who ex-perience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol 2001; 185: 748-53.
18. Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC. Proposals for the measurement of anti-be-ta2-glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost 2004; 2: 1860-2.
19. Ichikawa K, Tsutsumi A, Atsumi T, Matsuura E, Kobayashi S, Hughes GR et al. A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies. Arthritis Rheum 1999; 42: 2461-70
20. Bahar AM, Kwak JY, Beer AE, Kim JH, Nelson LA, Beaman KD, et al. Antibodies to phospholipids and nu-clear antigens in non-pregnant women with unexplained spontaneous recurrent abortion. J Reprod Immunol 1993; 24: 213-22.
21. Spadaro A, Riccieri V, Terracina S, Rinaldi T, Taccari E, Zoppini A. Class specific rheumatoid factors and antiphospholipid sindrome in systemic lupus erythe-matosus. Lupus 2000; 9: 56-60.
22. Iverson GM, von M hlen CA, Staub HL, Lassen AJ, Binder W, Norman GL. Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI. J Autoimmun 2006; 27: 266-271
23. Cugno M, Cabibbe M, Galli M, Caccia S, Russo R et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid sindrome: evidence of interaction between the antibodies and the catalytic do-main of tPA in 2 patients. Blood 2004; 103: 2121-6.
24. Cugno M, Dominguez M, Cabibbe M, Bisiani G, Gal-li M, Angles-Cano E et al. Antibodies to tissue-type plasminogen activator in plasma from patients with pri-mary antiphospholipid syndrome. Br J Haematol. 2000; 108: 871-5.
25. Bertolaccini ML, Mepani K, Sanna G, Hughes GR, Khamashta MA. Factor XII autoantibodies as a novel marker for thrombosis and adverse obstetric history in patients with systemic lupus erythematosus. Ann Rheum Dis. 2007; 66: 553-6.
26. Galli M, Borrelli G, Jacobsen EM, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the Antiphospholipid syndrome) study. Blood 2007; 110: 1178-83.
27. Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsut-sumi A, Matsuura E, et al. Association of autoantibod-ies against the phosphatidylserine-prothrombin com-plex with manifestations of the antiphospholipid syn-drome and the presence of lupus anticoagulant. Arthri-tis Rheum 2000; 43: 1982-93.
28. Galli M, Willems GM, Rosing J, Janssen RM, Govers-Riemslag JW, Comfurius P et al. Anti-prothrombin IgG, from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated pro-tein C. Br J Haematol 2005; 129: 240-7.
29. Field SL, Hogg PJ, Daly EB, Day YP, Murray B, Owens D et al. Lupus anticoagulants from immune complexes with prothrombin and phospholipid that can augment thrombin production in flow. Blood 1999; 94: 3421-31.
30. Arvieux J, Darnige L, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to pro-thrombin showing their prevalencein patients with lu-pus anticoagulants. Thromb Haemost 1995; 74:1120-5
31. Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological preperties of anti-prothrombin antibodies in patients with an-tiphospholipid antibodies. Thromb Haemost 1997; 77: 486-91.
32. Sanmarco M, Boffa MC. Antipho phatidylethanolamine antibodies and the antiphospholipid syndrome. Lupus 2009; 18: 920-3
33. Sanmarco M. Clinical significance of antiphosphatidylethanolamine antibodies in the so-called "seronegative antiphospholipid syndrome". Au-toimmun Rev 2009; 20.
34. Vlachoyiannopoulos PG, Beigbeder G, Dueymes M, Youinou P, Hunt JE, Krilis SA. Antibodies to phos-phatidylethanolamine in antiphospholipid syndrome and systemic lupus erytematosus: their correlation with anticardiolipin antibodies and beta 2 glycoprotein-I plasma levels. Autoimmunity 1993; 16: 245-9
35. Sanmarco M, Alessi MC, Harle JR, Sapin C, Aillaud MF, Gentile S. Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in pa-tients with unexplained thromboses. Thromb Haemost 2001; 58: 800-5.
36. Sanmarco M, Gayet S, Alessi MC, Audrain M, de Maistre E, Gris JC. Antiphosphatidylethanolamine an-tibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost 2007; 97:949-54.
37. Sugi T, Katsunuma J, Izumi S.I., McIntyre J.A. and Makino T, Prevalence and heterogenity of antipho-sphatidylethanolamine antibodies in patients withre-current early pregnancy losses, Fertil Steril 1999; 71: 1060-5.
38. Lanir N, Aharon A, Brenner B. Procoagulant and anti-coagulant mechanisms in human placenta. Semin Thromb Hemost 2003; 29: 175-84.
39. Meroni PL, Riboldi P. Pathogenic mechanisms mediating antiphospholipid syndrome. Curr Opin Rheuma-tol. 2001; 13: 377-82.
40. Salmon JE, Groot PG. Pathogenic role of an-tiphopholipid antibodies. Lupus 2008; 17: 405-11
41. Pierangeli SS, Gharavi AE, Harris En. Experimental thrombosis and antiphospholipid Antibodies: New in-sight. Journal of Autoimmunity. 2000; 15: 241-247
42. Raschi E, Broggini V, Grossi C, Borghi MO, Pieran-geli SS, Meroni PL. Mechanisms of Action of An-tiphospholipid Antibodies. Handbook of Systemic Au-toimmune Diseases. Antiphospholipid Syndrome in Systemic Autoimmune Disease 2009; 4: 55-67
43. Giannakopoulus B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphos-pholipid syndrome. Blood 2007; 109: 422-30
44. Ieko M, Sawada KI, Koike T, Notoya A, Mukai M, Kohno M et al. Semin Thromb Hemost. 1999, 25: 503-7.
45. Ieko M, Ichikawa K, Atsumi T, Takeuchi R, Sawada KI, Yasukouchi T et al.et al. Effects of beta2-glyco-protein I and monoclonal anticardiolipin antibodies on extrinsic fibrinolysis. Semin Thromb Hemost 2000; 26: 85-90.
46. Shi T, Giannakopoulos B, Yan X, Yu P, Berndt MC, Andrews RK et al. Antibeta2-Glycoprotein I antibod-ies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 2006; 54: 2558-67.
47. Pierangeli SS, Vega-Ostertag ME, Raschi E, Liu X, Romay-Penabad Z, De Micheli V et al. Toll-like re-ceptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis 2007; 66: 1327-33
48. Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Es-pinola RG, Salmon J. Requirement of activation of complement C3 and c5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005, 52:2120-4.
49. Oku K, Atsumi T, Bohgaki M, Amengual O, Kataoka H, Horita T et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009; 68: 1030-5.
50. Pierangeli SS, Chen PP, Raschi E, Scurati S, Grossi C, Borghi MO et al. Antiphospholipid Antibodies and the Anthiphospholipid Syndrome: Pathogenic Mechanism. Semin Thromb Hemost 2008; 34: 236-50.
51. Di Simone N, meroni PL, D'Asta M, D'Alessio MC, Caruso A. Pathogenic role of anti-b2-glycoprotein I an-tibodies on human placenta: functional effects related to implabtation and roles of heparin. Hum Reprod Up-date 2007; 13: 189-96.
52. Meroni PL, Gerosa M, Raschi E, Scurati S, Grossi C, Borghi Mo. Updating on the pathogenic mechanism 5 of the antiphospholipid antibodies-associated pregnan-cy loss. Clinic Rev Allerg Immunol 2008; 34: 332-7
53. Espinosa G, Cervera R. Antiphospholipid Syndrome. Arthritis Res Ther 2008; 10: 230.
54. Miyakis S, Lockshin MD, Atsumi D, Branch DW, Brey RL, Cervera R et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
55. Pengo V, Ruffatti A. Laboratory diagnosis of an-tiphospholipid syndrome. Reumatismo 2007; 59: 187-91.
56. Shoenfeld Y, Blank M, Cervera R, Font J, Raschi E, Meroni PL. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 2006; 65: 2-6.
57. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noven-ta F, Iliceto S. Antibody profiles for the diagnosis of an-tiphospholipid syndrome. Thromb Haemost 2005; 93: 1147-52.
58. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in do-main I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005; 105: 1540-5.
59. Martinuzzo ME, Forastiero RR, Carreras LO. Anti-2-Glycoprotein-I antibodies detection and association-with thrombosis. Br J Haematol 1995; 89: 397-402
60. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anti-coagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syn-drome: a systematic review of the literature. Blood 2003; 101: 1827-32.
61. Asherson RA. New subsets of the antiphospholipid syn-drome in 2006: "PRE-APS (probable APS)" and microangiopathic antiphospholipid syndromes ("MAPS"). Autoimmun Rev 2006; 6: 76-80.
62. Asherson RA; Espinosa G, Cervera R, Gomez-Puerta JA, Musuruana J, Bucciarelli S et al. Disseminated in-travascular coagulation in catastrophic antiphospho-lipid syndrome: clinical and haematological character-istics of 23 patients. Ann Rheum Dis 2005; 64: 943-6.
63. Asherson R, Cervera R, Merrill J. Thrombotic mi-croangiopathic antiphospholipid syndromes: a contin-uum of conditions? Future Rheumatol 2006; 1: 1-9.
64. Hughes GR, Khamashta MA. Seronegative antiphos-pholipid syndrome. Ann Rheum Dis 2003; 62: 1127
65. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Eng J med. 2002; 346: 752-63.
66. James AH, Brancazio LR, Price T. Aspirin and repro-ductive outcomes. Obstet Gynecol Surv 2008; 63:49-57.
67. Meroni PL, Mari D, Monti D, Coppola R, Capri M, Sal-violi S et al. Anti-beta 2 glycoprotein I antibodies in centenarians. Exp Gerontol 2004; 39:1459-65.
68. Ferraccioli GF, Gremese E. Autoantibodies and throm-bophilia in RA: TNFalpha and TNFalpha blockers. Ann Rheum Dis 2004; 63: 613-5.
69. Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, et al. Treatment with tu-mour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 2004; 63: 1075-8.